SB-497115-GR 12.5mg
108109
Phase 3 small_molecule completed
Quick answer
SB-497115-GR 12.5mg for Chronic Idiopathic Thrombocytopenic Purpura is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Chronic Idiopathic Thrombocytopenic Purpura
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed